Home »
University of North Carolina Lineberger Comprehensive Cancer Center researchers have discovered a promising method to identify aggressive breast cancer tumors that will respond to drugs that unleash the immune system against cancer. The U.S. Food and Drug Administration recently approved a treatment that combines an immunotherapy drug and chemotherapy for triple negative breast cancer, but […]
An international team of researchers has found a different way cancer becomes resistant to chemotherapy, suggesting a new target for drugs. Chemotherapy kills cancers cells by preventing them from multiplying and by inducing ‘cell death’, a natural process that can be enhanced with drugs. One form of cell death, called ferroptosis—iron-dependent cell death—is caused by […]
The International Atomic Energy Agency (IAEA) and St. Jude Children’s Research Hospital are joining forces to combat childhood cancers in developing countries, where children are four times more likely to die of the disease than in high-income countries due to a lack of affordable treatment and quality care options. Under a new agreement signed today, […]
Scientists at Massey University in New Zealand have taken the first step towards a new class of drug that could stop cancer from becoming resistant to treatment. Treatment resistance is a serious problem to the successful treatment of cancer patients because it leads to cancer returning and becoming harder to treat. The new class of […]
RESILIENT was a single arm, open label, phase II/III study to test if label agnostic therapy regimens guided by Encyclopedic Tumor Analysis can offer meaningful clinical benefit for patients with relapsed refractory metastatic malignancies. Patients with advanced refractory solid organ malignancies where disease had progressed following 2 lines of systemic treatments were enrolled in the […]
Now, a new Salk Institute study, published on July 24, 2019, in the journal Science Advances, shows that researchers could target these hard-to-treat cancers by pursuing drugs that keep a cellular “switch,” called CREB, from triggering tumor growth. The study was led by Marc Montminy, professor and J.W. Kieckhefer Foundation Chair at Salk, in close […]
Cancers can make themselves harder for new immunotherapies to see by ‘changing their spots’ – and switching off a key molecule on the surface of cells that is otherwise recognised by treatment. Researchers found that they could test samples from patients with bowel cancer to identify which were most likely to respond to immunotherapy by […]
Researchers from the University of Michigan Rogel Cancer Center have found that a genetic mutation seen in about half of all brain tumors produces a response that prevents radiation treatment from working. Altering that response using FDA-approved drugs restores tumors’ sensitivity to radiation therapy, extending survival in mice. The paper, representing more than five years […]
Researchers at the Johns Hopkins Kimmel Cancer Center discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, demonstrating a possible pathway for treatment of people with pancreatic cancers whose response to standard immunotherapy is poor. Results of the experiments combining an immune system booster vaccine called PancVAX […]
The spread of invasive cancer cells from a tumor’s original site to distant parts of the body is known as metastasis. It is the leading cause of death in people with cancer. In a paper published online in iScience, University of California San Diego School of Medicine researchers reported engineering sensors that can detect and […]